NCR 100
Alternative Names: NCR-100Latest Information Update: 23 Dec 2024
Price :
$50 *
At a glance
- Originator Nuwacell Biotechnologies
- Class Mesenchymal stem cell therapies; Pluripotent stem cell therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 12 Dec 2024 Nuwacell Biotechnologies plans phase I/II trial in Osteoarthritis in February 2025 (Intra-articular, Injection) (NCT06741098)
- 31 Oct 2023 Nuwacell Biotechnologies plans a phase I trial for Osteoarthritis in October 2023 (Intra-articular) (NCT06049342)
- 29 Sep 2023 Preclinical trials in Osteoarthritis in China (Intra-articular)